Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned an average recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.7692.

A number of equities research analysts have recently issued reports on CMPX shares. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group decreased their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday, April 28th. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 27th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Compass Therapeutics during the second quarter worth about $24,707,000. Palo Alto Investors LP acquired a new position in Compass Therapeutics during the second quarter worth approximately $12,771,670,000. Vivo Capital LLC raised its stake in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares during the period. BVF Inc. IL raised its stake in Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after buying an additional 3,014,842 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in Compass Therapeutics in the third quarter valued at approximately $9,892,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

NASDAQ:CMPX opened at $2.48 on Friday. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The company has a market cap of $446.62 million, a P/E ratio of -6.20 and a beta of 0.92. The stock’s 50-day simple moving average is $2.13 and its 200 day simple moving average is $3.64.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities analysts predict that Compass Therapeutics will post -0.46 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.